Dear stakeholders,
We are writing to inform you that the discussion for ID3757 - Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer, will now take place at the HST committee on 15 March 2023, instead of the Technology Appraisals D meeting on 16 March 2023. This change is to ensure there is enough time to discuss this topic in full during the meeting.
If you have any questions about this change, please contact scheduling@nice.org.uk.